股本结构
单位：万股
| 公告日期 | 2024-04-23 | 2024-02-05 | 2024-02-22 | 2023-11-14 | 2023-11-14 | 2023-08-03 |
|---|---|---|---|---|---|---|
| 证券总股本 | 9007.90 | 8992.90 | 4517.77 | 4514.54 | 4459.54 | 4459.54 |
| 普通股本 | 9007.90 | 8992.90 | 4517.77 | 4514.54 | 4459.54 | 4459.54 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2024-03-31 | 2024-01-17 | 2023-12-31 | 2023-10-31 | 2023-09-30 | 2023-07-28 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2024-04-23 | 9007.90 | 未披露 | 定期报告 | 2024-03-31 |
| 2024-02-05 | 8992.90 | 未披露 | 定期报告 | 2024-01-17 |
| 2024-02-22 | 4517.77 | 未披露 |
更多>>
From December 31, 2022 to December 31, 2023
Shares issued from exercise of pre-funded warrants
Issuance of common stock - At The Market Sales Agreement net of issuance costs of $26
Shares issued in connection with the Company's employee stock purchase plan
|
2023-12-31 |
| 2023-11-14 | 4514.54 | 未披露 | 定期报告 | 2023-10-31 |
| 2023-11-14 | 4459.54 | 未披露 |
更多>>
From June 30, 2023 to September 30, 2023
Issuance of common stock - at the market Sales Agreement net of issuance costs of $9
|
2023-09-30 |
| 2023-08-03 | 4459.54 | 未披露 | 定期报告 | 2023-07-28 |
| 2023-08-03 | 4448.84 | 未披露 |
更多>>
From March 31, 2023 to June 30, 2023
Shares issued in connection with the Company's Employee stock purchase plan
|
2023-06-30 |
| 2023-05-11 | 4440.38 | 未披露 |
更多>>
From January 1, 2023 to March 31, 2023
Shares issued from exercise of pre-funded warrants
|
2023-03-31 |
| 2023-02-23 | 4440.38 | 未披露 | 定期报告 | 2023-02-17 |
| 2023-02-23 | 3930.73 | 未披露 |
更多>>
From December 31, 2021 to December 31,2022
Issuance of common stock and Pre-funded Warrants - October 2022 PIPE transaction, net of issuance costs of $4,012,000
Issuance of common stock - At The Market Sales Agreement net of issuance costs of $1,226,000
Shares issued in connection with the Company's employee stock purchase plan
Shares issued in connection with the Company's stock option plan
|
2022-12-31 |
| 2022-12-09 | 4435.81 | 未披露 | 定期报告 | 2022-11-30 |
| 2022-11-03 | 3926.15 | 未披露 | 定期报告 | 2022-10-28 |
| 2022-08-04 | 3056.50 | 未披露 |
更多>>
From March 31, 2022 to June 30, 2022
Shares issued in connection with the Company's Employee stock purchase plan
Issuance of common stock - at the market Sales Agreement net of issuance costs of $308
|
2022-06-30 |
| 2022-05-10 | 3054.04 | 未披露 | 定期报告 | 2022-05-02 |
| 2022-05-02 | 2965.97 | 未披露 | 定期报告 | 2022-04-29 |
| 2022-04-27 | 3054.04 | 未披露 | 定期报告 | 2022-04-14 |
| 2022-05-10 | 2924.04 | 未披露 |
更多>>
From January 1, 2022 to March 31, 2022
Shares issued in connection with the Company's stock option plan
Issuance of common stock - At The Market Sales Agreement net of issuance costs of $918
|
2022-03-31 |
| 2022-04-27 | 2891.00 | 未披露 | 定期报告 | 2022-03-15 |
| 2022-02-24 | 2790.69 | 未披露 | 定期报告 | 2022-02-18 |
| 2022-02-24 | 2633.54 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Issuance of common stock - July 2021 equity offering net of issuance costs of $2,980
Issuance of common stock - At The Market Sales Agreement net of issuance costs of $23
Shares issued in connection with the Company's employee stock purchase plan
Issuance of common stock in connection with the 4SC royalty settlement
|
2021-12-31 |
| 2021-11-04 | 2624.94 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Issuance of common stock - July 2021 equity offering net of issuance costs of $2,980
|
2021-09-30 |
| 2021-07-19 | 2624.94 | 未披露 |
更多>>
1.Common stock offered 4,500,000 shares.
2.Unless otherwise stated, all information in this prospectus supplement is based on 21,749,439 shares of common stock outstanding as of June 30, 2021.
|
2021-07-19 |
| 2021-05-06 | 2174.94 | 未披露 |
更多>>
From December 31, 2020 to March 31, 2021
Issuance of common stock in connection with the 4SC royalty settlement
|
2021-03-31 |
| 2021-02-26 | 2116.82 | 未披露 |
更多>>
From December 31, 2019 to December 31, 2020
Issuance of common stock - At The Market Sales Agreement net of issuance costs of $339
Issuance of common stock - April registered direct equity offering net of issuance costs of $1,082
Issuance of common stock - June public equity offering net of issuance costs of $1,752
Issuance of common stock - August public equity offering net of issuance costs of $6,960
|
2020-12-31 |
| 2020-11-06 | 2071.83 | 未披露 |
更多>>
From June 30, 2020 to September 30, 2020
Issuance of common stock-August public equity offering net of issuance costs of $6,960,000
|
2020-09-30 |
| 2020-08-07 | 1996.83 | 未披露 |
更多>>
1.Common stock offered 5,000,000 shares.
2.Unless otherwise stated, all information in this prospectus supplement is based on 14,968,340 shares of common stock outstanding as of June 30, 2020.
|
2020-08-07 |
| 2020-08-03 | 1496.83 | 未披露 |
更多>>
From March 31, 2020 to June 30, 2020
Issuance of common stock - April registered direct equity offering net of issuance costs of $1,082
Issuance of common stock - June public equity offering net of issuance costs of$1,752
Issuance of common stock - At The Market Sales Agreement net of issuance costs of $75
|
2020-06-30 |
| 2020-06-12 | 1496.83 | 未披露 |
更多>>
1.Common Stock Offered 2,175,000 shares
2.The number of shares of our common stock to be outstanding immediately before and after this offering is based on 12,793,340 shares outstanding as of June 8, 2020
|
2020-06-12 |
| 2020-04-27 | 1279.33 | 未披露 |
更多>>
1.Common Stock Offered 1,764,706 shares
2.The number of shares of our common stock to be outstanding immediately before and after this offering is based on 11,028,634 shares outstanding as of April 22, 2020
|
2020-04-27 |
| 2020-04-29 | 1082.40 | 未披露 | 定期报告 | 2020-04-15 |
| 2020-05-08 | 1082.36 | 未披露 |
更多>>
From December 31, 2019 to March 31, 2020
Issuance of common stock - At The Market net of issuance costs $37
|
2020-03-31 |
| 2020-03-16 | 1074.48 | 未披露 |
更多>>
From December 31, 2018 to December 31, 2019
Conversion of Series A Preferred Stock to common stock
Issuance of common stock in pre-closing financing for cash, net of issuance costs of $61
Issuance of common stock - Bonus share agreement
Issuance of common stock - settlement of contingent payment
Exchange of common stock in connection with Transaction
Issuance of common stock under restricted stock unit agreements
Public offering of common stock - net of issuance costs $377
|
2019-12-31 |
| 2019-11-07 | 1011.70 | 未披露 | 定期报告 | 2019-11-01 |
| 2019-11-07 | 1007.07 | 未披露 |
更多>>
from July 1, 2019 to September 30, 2019
Issuance of common stock under restricted stock unit agreements
Public offering of common stock - net of issuance costs $144
|
2019-09-30 |
| 2019-08-08 | 1009.35 | 未披露 | 定期报告 | 2019-08-06 |
| 2019-08-08 | 998.64 | 未披露 |
更多>>
From March 31, 2019 To June 30, 2019
Conversion of Series A Preferred Stock to common stock
Issuance of common stock in pre-closing financing for cash, net of issuance costs of $61
Issuance of common stock - Executive bonus agreement
Issuance of common stock - settlement of contingent payment
Exchange of common stock in connection with Transaction
|
2019-06-30 |
| 2019-06-18 | 998.64 | 未披露 | 定期报告 | 2019-06-17 |
| 2019-04-15 | 1010.00 | 未披露 |
更多>>
On April 4, 2019, the stockholders of Vital Therapies approved the stock-for-stock transaction. Immediately prior to the transaction, the company effectuated a 40:1 reverse stock split of shares of its common stock. Following the closing of the transaction and the reverse stock split, there were approximately 10.1 million issued and outstanding shares of the company's common stock. As a result of a higher company net cash balance at closing, the final exchange ratio resulted in pre-closing Vital Therapies stockholders owning approximately 11.75% of the company, instead of the estimated previously disclosed 11%.
|
2019-04-15 |
| 2019-03-04 | 4236.97 | 未披露 |
更多>>
from December 31, 2017 to September 30, 2018
Exercise of stock options
|
2018-09-30 |
| 2018-08-07 | 4236.94 | 未披露 | 定期报告 | 2018-07-31 |
| 2018-08-07 | 4236.90 | 未披露 | 定期报告 | 2018-06-30 |
| 2018-05-08 | 4236.90 | 未披露 | 定期报告 | 2018-04-30 |
| 2018-03-13 | 4236.89 | 未披露 |
更多>>
from December 31, 2016 to December 31, 2017
Exercise of stock options
Common stock issued for services
Issuance of common stock, net of issuance costs
|
2017-12-31 |
| 2017-05-09 | 4220.74 | 未披露 | 定期报告 | 2017-03-31 |
| 2017-04-11 | 4089.49 | 未披露 | 定期报告 | 2017-03-29 |
| 2017-03-07 | 3214.49 | 未披露 | 定期报告 | 2017-02-28 |
| 2017-03-07 | 3214.35 | 未披露 |
更多>>
from December 31, 2015 to December 31, 2016
Exercise of stock options and change in stock option early exercise repurchase liability
Issuance of common stock, net of issuance costs
|
2016-12-31 |
| 2016-11-03 | 3205.09 | 未披露 | 定期报告 | 2016-10-31 |
| 2016-11-03 | 3194.89 | 未披露 | 定期报告 | 2016-09-30 |
| 2016-08-02 | 3154.09 | 未披露 | 定期报告 | 2016-07-31 |
| 2016-08-02 | 3153.91 | 未披露 | 定期报告 | 2016-06-30 |
| 2016-05-09 | 3124.44 | 未披露 | 定期报告 | 2016-04-30 |
| 2016-05-09 | 3098.02 | 未披露 | 定期报告 | 2016-03-31 |
| 2016-04-14 | 3098.02 | 未披露 | 定期报告 | 2016-03-30 |
| 2016-03-08 | 3047.43 | 未披露 | 定期报告 | 2016-02-29 |
| 2016-03-08 | 3047.31 | 未披露 |
更多>>
from December 31, 2014 to December 31, 2015
Exercise of stock options and change in stock option early exercise repurchase liability
Issuance of common stock, net of issuance costs
|
2015-12-31 |
| 2015-11-05 | 3042.57 | 未披露 | 定期报告 | 2015-10-31 |
| 2015-11-05 | 2414.57 | 未披露 | 定期报告 | 2015-09-30 |
| 2015-10-07 | 2414.57 | 未披露 | 定期报告 | 2015-09-22 |
| 2015-08-06 | 2401.58 | 未披露 | 定期报告 | 2015-07-31 |
| 2015-08-06 | 2401.45 | 未披露 | 定期报告 | 2015-06-30 |
| 2015-05-12 | 2401.23 | 未披露 | 定期报告 | 2015-04-30 |
| 2015-05-12 | 2401.04 | 未披露 | 定期报告 | 2015-03-31 |
| 2015-03-20 | 2399.34 | 未披露 | 定期报告 | 2015-02-27 |
| 2015-03-20 | 2398.28 | 未披露 |
更多>>
from December 31, 2013 to December 31, 2014
Private placement senior redeemable convertible preferred stock — from January to March 2014
Conversion of redeemable convertible preferred stock to common stock
Exercise of stock options and release of stock option early exercise repurchase liability
Initial public offering, net of issuance costs
Adjustment for fractional shares
Issuance of common stock, net of issuance costs
|
2014-12-31 |
| 2014-11-13 | 2384.52 | 未披露 | 定期报告 | 2014-11-07 |
| 2014-11-13 | 2179.09 | 未披露 | 定期报告 | 2014-09-30 |
| 2014-09-22 | 2179.09 | 未披露 | 定期报告 | 2014-08-31 |
| 2014-08-07 | 2179.07 | 未披露 | 定期报告 | 2014-06-30 |
| 2014-05-28 | 2179.07 | 未披露 | 定期报告 | 2014-05-27 |
| 2014-04-17 | 2111.57 | 未披露 |
更多>>
The conversion of all outstanding shares of our preferred stock into an aggregate of 16,009,423 shares of common stock upon the closing of this offering
|
2014-04-17 |
| 2014-04-03 | 60.62 | 1600.94 | 定期报告 | 2014-02-28 |
| 2014-03-11 | 60.62 | 1371.34 | 定期报告 | 2013-12-31 |
| 2013-10-30 | 60.62 | 1131.34 |
更多>>
from December 31, 2012 to September 30, 2013
Private placement senior redeemable convertible preferred stock – from February 28 to June 26, 2013
Exercise of stock options, net of repurchase liability
|
2013-09-30 |
| 2013-10-11 | 60.62 | 1131.34 |
更多>>
from December 31, 2012 to June 30, 2013
Private placement senior redeemable convertible preferred stock – from February 28 to June 26, 2013
Exercise of stock options, net of repurchase liability
|
2013-06-30 |
From December 31, 2022 to December 31, 2023
Shares issued from exercise of pre-funded warrants
Issuance of common stock - At The Market Sales Agreement net of issuance costs of $26
Shares issued in connection with the Company's employee stock purchase plan
From June 30, 2023 to September 30, 2023
Issuance of common stock - at the market Sales Agreement net of issuance costs of $9
From March 31, 2023 to June 30, 2023
Shares issued in connection with the Company's Employee stock purchase plan
From January 1, 2023 to March 31, 2023
Shares issued from exercise of pre-funded warrants
From December 31, 2021 to December 31,2022
Issuance of common stock and Pre-funded Warrants - October 2022 PIPE transaction, net of issuance costs of $4,012,000
Issuance of common stock - At The Market Sales Agreement net of issuance costs of $1,226,000
Shares issued in connection with the Company's employee stock purchase plan
Shares issued in connection with the Company's stock option plan
From March 31, 2022 to June 30, 2022
Shares issued in connection with the Company's Employee stock purchase plan
Issuance of common stock - at the market Sales Agreement net of issuance costs of $308
From January 1, 2022 to March 31, 2022
Shares issued in connection with the Company's stock option plan
Issuance of common stock - At The Market Sales Agreement net of issuance costs of $918
From December 31, 2020 to December 31, 2021
Issuance of common stock - July 2021 equity offering net of issuance costs of $2,980
Issuance of common stock - At The Market Sales Agreement net of issuance costs of $23
Shares issued in connection with the Company's employee stock purchase plan
Issuance of common stock in connection with the 4SC royalty settlement
From June 30, 2021 to September 30, 2021
Issuance of common stock - July 2021 equity offering net of issuance costs of $2,980
1.Common stock offered 4,500,000 shares.
2.Unless otherwise stated, all information in this prospectus supplement is based on 21,749,439 shares of common stock outstanding as of June 30, 2021.
From December 31, 2020 to March 31, 2021
Issuance of common stock in connection with the 4SC royalty settlement
From December 31, 2019 to December 31, 2020
Issuance of common stock - At The Market Sales Agreement net of issuance costs of $339
Issuance of common stock - April registered direct equity offering net of issuance costs of $1,082
Issuance of common stock - June public equity offering net of issuance costs of $1,752
Issuance of common stock - August public equity offering net of issuance costs of $6,960
From June 30, 2020 to September 30, 2020
Issuance of common stock-August public equity offering net of issuance costs of $6,960,000
1.Common stock offered 5,000,000 shares.
2.Unless otherwise stated, all information in this prospectus supplement is based on 14,968,340 shares of common stock outstanding as of June 30, 2020.
From March 31, 2020 to June 30, 2020
Issuance of common stock - April registered direct equity offering net of issuance costs of $1,082
Issuance of common stock - June public equity offering net of issuance costs of$1,752
Issuance of common stock - At The Market Sales Agreement net of issuance costs of $75
1.Common Stock Offered 2,175,000 shares
2.The number of shares of our common stock to be outstanding immediately before and after this offering is based on 12,793,340 shares outstanding as of June 8, 2020
1.Common Stock Offered 1,764,706 shares
2.The number of shares of our common stock to be outstanding immediately before and after this offering is based on 11,028,634 shares outstanding as of April 22, 2020
From December 31, 2019 to March 31, 2020
Issuance of common stock - At The Market net of issuance costs $37
From December 31, 2018 to December 31, 2019
Conversion of Series A Preferred Stock to common stock
Issuance of common stock in pre-closing financing for cash, net of issuance costs of $61
Issuance of common stock - Bonus share agreement
Issuance of common stock - settlement of contingent payment
Exchange of common stock in connection with Transaction
Issuance of common stock under restricted stock unit agreements
Public offering of common stock - net of issuance costs $377
from July 1, 2019 to September 30, 2019
Issuance of common stock under restricted stock unit agreements
Public offering of common stock - net of issuance costs $144
From March 31, 2019 To June 30, 2019
Conversion of Series A Preferred Stock to common stock
Issuance of common stock in pre-closing financing for cash, net of issuance costs of $61
Issuance of common stock - Executive bonus agreement
Issuance of common stock - settlement of contingent payment
Exchange of common stock in connection with Transaction
On April 4, 2019, the stockholders of Vital Therapies approved the stock-for-stock transaction. Immediately prior to the transaction, the company effectuated a 40:1 reverse stock split of shares of its common stock. Following the closing of the transaction and the reverse stock split, there were approximately 10.1 million issued and outstanding shares of the company's common stock. As a result of a higher company net cash balance at closing, the final exchange ratio resulted in pre-closing Vital Therapies stockholders owning approximately 11.75% of the company, instead of the estimated previously disclosed 11%.
from December 31, 2017 to September 30, 2018
Exercise of stock options
from December 31, 2016 to December 31, 2017
Exercise of stock options
Common stock issued for services
Issuance of common stock, net of issuance costs
from December 31, 2015 to December 31, 2016
Exercise of stock options and change in stock option early exercise repurchase liability
Issuance of common stock, net of issuance costs
from December 31, 2014 to December 31, 2015
Exercise of stock options and change in stock option early exercise repurchase liability
Issuance of common stock, net of issuance costs
from December 31, 2013 to December 31, 2014
Private placement senior redeemable convertible preferred stock — from January to March 2014
Conversion of redeemable convertible preferred stock to common stock
Exercise of stock options and release of stock option early exercise repurchase liability
Initial public offering, net of issuance costs
Adjustment for fractional shares
Issuance of common stock, net of issuance costs
The conversion of all outstanding shares of our preferred stock into an aggregate of 16,009,423 shares of common stock upon the closing of this offering
from December 31, 2012 to September 30, 2013
Private placement senior redeemable convertible preferred stock – from February 28 to June 26, 2013
Exercise of stock options, net of repurchase liability
from December 31, 2012 to June 30, 2013
Private placement senior redeemable convertible preferred stock – from February 28 to June 26, 2013
Exercise of stock options, net of repurchase liability